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Background: Imerslund-Gräsbeck Syndrome (IGS) is a rare autosomal recessive disease characterized by intestinal
vitamin B12 malabsorption. Clinical features include megaloblastic anemia, recurrent infections, failure to thrive, and
proteinuria. Recessive mutations in cubilin (CUBN) and in amnionless (AMN) have been shown to cause IGS. To date,
there are only about 300 cases described worldwide with only 37 different mutations found in CUBN and 30 different
in the AMN gene.
Case presentation: We collected pedigree structure, clinical data, and DNA samples from 2 Caucasian English
half-sisters with IGS. Molecular diagnostics was performed by direct Sanger sequencing of all 62 exons of the
CUBN gene and 12 exons of the AMN gene. Because of lack of parental DNA, cloning, and sequencing of
multiple plasmid clones was performed to assess the allele of identified mutations. Genetic characterization
revealed 2 novel compound heterozygous AMN mutations in both half-sisters with IGS. Trans-configuration of
the mutations was confirmed.
Conclusion: We have identified novel compound heterozygous mutations in AMN in a family from the United
Kingdom with clinical features of Imerslund-Gräsbeck Syndrome.
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Imerslund-Gräsbeck Syndrome (IGS) is a rare autosomal
recessive disorder characterized by intestinal cobalamin
(vitamin B12) malabsorption usually leading to megalo-
blastic anemia in childhood. IGS was first described in 1960
by two physicians, Olga Imerslund from Norway [1] and
Ralph Gräsbeck from Finland [2]. Clinical features of IGS
include failure to thrive, recurrent infections, anemia, and
mild proteinuria. IGS should also be considered in individ-
uals with intermittent nephrotic-range proteinuria [3].
Genetic investigations in affected IGS families from
Finland identified bi-allelic mutations in the gene CUBN,
encoding cubilin [4] whilst in Norwegian families mutations* Correspondence: john.sayer@newcastle.ac.uk
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many additional genetically confirmed cases have been re-
ported with about 300 IGS cases published worldwide [6].
IGS is thought to have a prevalence of about 1/200,000
with a geographical concentration in Scandinavia and the
Middle East [7]. Most of the published cases have been
identified in Finland, Norway and eastern Mediterranean
countries frequently in consanguineous families [8]. To
date, only 37 different mutations in CUBN and 30 different
mutations in AMN have been reported in the “Human
Gene Mutation Database” (HGMD) worldwide (http://
www.hgmd.cf.ac.uk/ac/index.php).
Cubilin and amnionless are required for intestinal ab-
sorption of intrinsic factor-vitamin B12 complex and renal
proximal tubular absorption of filtered plasma proteins.
Cubilin is a large (460 kDa) membrane-associated multili-
gand receptor and amnionless is a 50 kDa type 1 trans-
membrane protein [9]. Together they function as acess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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teins are highly expressed in the small intestine and
proximal tubule of the kidney. Within the proximal tu-
bule they interact with megalin (a multi-ligand binding
receptor encoded by LRP2), allowing reabsorption of
low molecular weight (LMW) proteins including albumin
[11]. Mutations in GIF, encoding gastric intrinsic factor
may give a similar hematological and clinical picture, but
this is classed as a hereditary intrinsic factor deficiency
and should not be confused with IGS [12].
The uptake of LMW proteins within in the kidney ini-
tially involves filtration in the glomerulus and then re-
absorption within the tubules [13]. Almost all the filtered
plasma proteins are reabsorbed in the renal proximal tu-
bule by receptor-mediated endocytosis. The only identified
receptors mediating this endocytosis are megalin and
cubilin. There are multiple recognised ligands for cubilin
and megalin [14]. Once the ligand binds to the receptor at
the apical plasma membrane, it is internalised via a vesicle.
Acidification within the intra-vesicular lumen then causes
the receptor and ligand to separate. The ligand is then
transported to its required location and the receptor
recycled back into the luminal membrane. Studies in
murine models indicate that within the tubule, megalin
functions mainly to facilitate the internalisation of the
cubilin–albumin complex [15]. As the normal function-
ing of cubulin is dependent on amnionless, defects in ei-
ther cubilin or amnionless result in reduced protein
reabsorption and subsequent LMW proteinuria. In IGS,
published cases have suggested that the proteinuria is
non-progressive and has not been associated with clin-
ical kidney disease hence renal function is preserved
[16]. Although vitamin B12 replacement corrects haem-
atological parameters, proteinuria usually persists.
Interestingly there have been cases of confirmed IGS,
where LMW proteinuria is not present. Currently no clearFig. 1 Pedigree diagram of family and chromatograms of AMN mutations
sibship with Imerslund-Gräsbeck syndrome. Circles represent females, squa
presumed carrier status. b Chromatograms of 2 novel compound heterozy
for the protein amnionless, identified in 2 half-sisters (III-1 and III-2) with Imlink has been identified to associate specific mutations to
clinical correlations, however with increasing identifica-
tion of mutations, it appears that functional null muta-
tions in the cubilin or amnionless gene are more likely to
be associated with proteinuria than those with a missense
mutation [17].
Here we report novel compound heterozygous muta-
tions in AMN in 2 half-sisters from the United Kingdom.
Case presentation
We identified a Caucasian English family in whom two
half-sisters had a clinical diagnosis of IGS (Fig. 1). In both
cases, clinical presentation had been at an early age. The
eldest sister (III:1) was diagnosed with pernicious anemia at
the age of 2 years and was commenced and continued on
vitamin B12 supplementation since then. Sub-nephrotic
range proteinuria was first identified on urine dipstix
testing during her teenage years but was not formally quan-
tified until her first pregnancy at 33 years of age. Her pro-
teinuria was non progressive, and was not associated with
hypertension or pre-eclampsia and persisted at similar
levels (0.6–0.7 g/24 h) post-natally. Similarly, the younger
sister (III:2) also presented with anemia aged 3 years and
has been successfully managed with vitamin B12 sup-
plementation. In patient III:2, proteinuria was also first
identified at 10 years of age and then quantified (at a
sub-nephrotic range) during her pregnancy (age 23 years)
and has persisted at similar levels since then. Proteinuria
was documented at 0.5 g/24 h at 36 weeks gestation and
by delivery (38 weeks gestation) proteinuria had reached
0.9 g/24 h, without the development of systolic hyperten-
sion. Postpartum she continued to have persisting sub-
nephrotic range proteinuria (0.7 g/24 h). A summary of
clinical details is provided in Table 1.
Both sisters were commenced on 3 monthly vitamin
B12 supplementation in early childhood and abnormalitiesin a family with Imerslund-Gräsbeck syndrome. a Pedigree diagram of a
res represent males. Full symbols denote patients with IGS, dots equals
gous mutations in the gene AMN (Genbank NM_030943.3), encoding
erslund-Gräsbeck syndrome
























III:1 2 Yes 405 64 50–90 56–84 73 0.6–0.7 No
III:2 3 Yes 743 62 66–71 64–90 76 0.65 No
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have been no identified neurological abnormalities in ei-
ther sibling however multiple urinary tract infections were
reported and documented in both sisters throughout
their teenage years and into adulthood. The half-sisters
continue to receive B12 supplementation however, des-
pite well maintained haemoglobin levels, both siblings
continue to experience symptoms of lethargy and tired-
ness. Sister III:1 became anemic during her pregnancy
and required extra B12 supplementation along with iron
supplementation.
Careful review of the family history revealed that each
of the half-sisters’ fathers were brothers, which was com-
patible with an autosomal recessive pattern of disease
(Fig. 1a). We therefore examined the underlying genetic
cause of IGS in this family by performing direct Sanger
sequencing of the genes AMN (12 exons) and CUBN (67
exons) known to be implicated in autosomal recessive
IGS. Mutation analysis revealed two novel compound het-
erozygous mutations in the AMN gene in both affected
half-sisters. We identified a heterozygous deletion of an
adenine nucleotide in exon 1, leading to a frame shift
and predicted premature stop 5 codons downstream
(c.35delA, p.Gln12Argfs*5) and we found a heterozy-
gous missense mutation (c.206 T > A, p.Met69Lys) in
exon 3 of the AMN gene (Fig. 1b). Both mutations have
not been reported in any public database including “The
Exome Aggregation Consortium” (ExAC) data set with
exome sequence data obtained from 63,352 individuals
(http://exac.broadinstitute.org/).
Since the patients’ mother was deceased and both fa-
thers were uncontactable, no parental DNA material was
available for segregation analysis of the mutations. To
determine whether the mutations were inherited in cis
or trans, we amplified and cloned the respective genomic
region encompassing the location of both identified AMN
mutations. We successfully amplified and cloned a 1.533 kb
PCR product, which included AMN exon 1 to 3. Subse-
quently, we performed direct Sanger sequencing of 24 inde-
pendent clones, 12 for each patient. Sequencing analysis
revealed 12 clones which contained only the exon 1 frame-
shift mutation (p.Gln12Argfs*5) and 11 clones showing ex-
clusively the exon 3 missense mutation (p.Met69Lys)
indicating inheritance from both parents and confirming
the presence of a compound heterozygous mutations.
Whereas the frameshift mutation is obviously most likelypathogenic, the missense mutation is predicted to be disease
causing by various web-based in silico prediction programs
including “Mutation Taster” (http://www.mutationtaster.org/),
‘Sorting Tolerant From Intolerant’ (SIFT) algorithm (http://
siftdna.org/), and Panther (http://www.pantherdb.org/). In
contrast, the PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/index.shtml) program predicts that the amnionless
p.Met69Lys missense variant might be a benign amino acid
change (score: 0.131).
Additionally, the direct sequencing of the CUBN gene re-
vealed the presence of a heterozygous missense variant
p.Val2865Met in exon 52 in both affected half-sisters. This
variant (rs146847375) has been reported in the Exome Vari-
ant Server (EVS) database (http://evs.gs.washington.edu/
EVS/) and is present in 6/4294 (0.14 %) European
Americans with a pathogenic polyphen-2 prediction
score of 0.996. We did not find any additional potential
heterozygous variants in CUBN in our patients. This al-
most excludes CUBN defects as disease causing in this
family, although, we can’t fully exclude the possibility that
this heterozygous CUBN variant might contribute to the
disease phenotype in our patients with bi-allelic AMN
mutations. CUBN is a very large exon-rich gene with
more than 200 different missense or truncating variants
reported in the EVS database predicted to be possibly or
probably protein damaging. Therefore, we reason that the
p.Val2865Met missense variant has been an incidental
finding. Cases of digenic mutations, where there is one
mutant allele in CUBN and one in AMN have to our
knowledge never been reported.
Conclusion
Using targeted Sanger sequencing of AMN and CUBN,
we identified novel compound heterozygous mutations in
AMN in a family from the United Kingdom with typical
clinical features of Imerslund-Gräsbeck Syndrome.
Consent
Following informed consent, DNA was obtained from both
affected patients. This study was approved by the Northern
and Yorkshire Regional Ethics Committee. Patients have
given their consent for the Case reports to be published.
Abbreviations
EVS: Exome Variant Server; ExAC: Exome Aggregation Consortium;
HGMD: Human Gene Mutation Database; IGS: Imerslund-Gräsbeck Syndrome;
LMW: Low molecular weight; SIFT: Sorting Tolerant From Intolerant.
Montgomery et al. BMC Medical Genetics  (2015) 16:35 Page 4 of 4Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EM drafted the manuscript. AMH, VVW and EAO carried out the molecular
genetic studies and drafted the manuscript, LB, SJ and JAG contributed
clinical data and revised it critically for important intellectual content. JAS
conceived of the study, and participated in its design and coordination and
helped to draft and revise the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
We acknowledge generous support from the Northern Counties Kidney
Research Fund (http://www.nckrf.org.uk/).
Author details
1Renal Services Centre, Freeman Hospital, Newcastle upon Tyne NHS
Hospitals Foundation Trust Newcastle upon Tyne, Newcastle upon Tyne NE7
7DN, UK. 2Institute of Genetic Medicine, Centre for Life, Newcastle Upon
Tyne, UK. 3Department of Pediatrics, University of Michigan, Ann Arbor, MI,
USA. 4Paediatric Nephrology, Royal Victoria Infirmary, Newcastle upon Tyne
NHS Hospitals Foundation Trust, Newcastle upon Tyne N1 4LP, UK.
Received: 22 January 2015 Accepted: 29 May 2015
References
1. Imerslund O. Idiopathic chronic megaloblastic anemia in children. Acta
Paediatr Suppl. 1960;49 Suppl 119:1–115.
2. Grasbeck R, Gordin R, Kantero I, Kuhlback B. Selective vitamin B12
malabsorption and proteinuria in young people. A syndrome Acta Med
Scand. 1960;167:289–96.
3. Ovunc B, Otto EA, Vega-Warner V, Saisawat P, Ashraf S, Ramaswami G, et al.
Exome sequencing reveals cubilin mutation as a single-gene cause of
proteinuria. J Am Soc Nephrol. 2011;22:1815–20.
4. Aminoff M, Carter JE, Chadwick RB, Johnson C, Grasbeck R, Abdelaal MA, et al.
Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin,
cause hereditary megaloblastic anaemia 1. Nat Genet. 1999;21:309–13.
5. Tanner SM, Aminoff M, Wright FA, Liyanarachchi S, Kuronen M, Saarinen A,
et al. Amnionless, essential for mouse gastrulation, is mutated in recessive
hereditary megaloblastic anemia. Nat Genet. 2003;33:426–9.
6. Grasbeck R, Tanner SM. Juvenile selective vitamin B12 malabsorption:
50 years after its description-10 years of genetic testing. Pediatr Res.
2011;70:222–8.
7. Tanner SM, Li Z, Bisson R, Acar C, Oner C, Oner R, et al. Genetically
heterogeneous selective intestinal malabsorption of vitamin B12: founder
effects, consanguinity, and high clinical awareness explain aggregations in
Scandinavia and the Middle East. Hum Mutat. 2004;23:327–33.
8. Tanner SM, Sturm AC, Baack EC, Liyanarachchi S, de la Chapelle A. Inherited
cobalamin malabsorption. Mutations in three genes reveal functional and
ethnic patterns Orphanet J Rare Dis. 2012;7:56.
9. Kalantry S, Manning S, Haub O, Tomihara-Newberger C, Lee HG, Fangman J,
et al. The amnionless gene, essential for mouse gastrulation, encodes a
visceral-endoderm-specific protein with an extracellular cysteine-rich
domain. Nat Genet. 2001;27:412–6.
10. Fyfe JC, Madsen M, Hojrup P, Christensen EI, Tanner SM, de la Chapelle A,
et al. The functional cobalamin (vitamin B12)-intrinsic factor receptor is a
novel complex of cubilin and amnionless. Blood. 2004;103:1573–9.
11. Zhai XY, Nielsen R, Birn H, Drumm K, Mildenberger S, Freudinger R, et al.
Cubilin- and megalin-mediated uptake of albumin in cultured proximal
tubule cells of opossum kidney. Kidney Int. 2000;58:1523–33.
12. Tanner SM, Li Z, Perko JD, Oner C, Cetin M, Altay C, et al. Hereditary juvenile
cobalamin deficiency caused by mutations in the intrinsic factor gene.
Proc Natl Acad Sci U S A. 2005;102:4130–3.
13. Dickson LE, Wagner MC, Sandoval RM, Molitoris BA. The proximal tubule
and albuminuria: really! J Am Soc Nephrol. 2014;25:443–53.
14. Verroust PA, Christensen EA. Megalin and cubilin–the story of two
multipurpose receptors. Neph Dial Transpl. 2002;17:1867–71.
15. Amsellem S, Gburek J, Hamard G, Nielsen R, Willnow TE, Devuyst O, et al.
Cubilin is essential for albumin reabsorption in the renal proximal tubule.
J Am Soc Nephrol. 2010;21:1859–67.16. Wahlstedt-Froberg V, Pettersson T, Aminoff M, Dugue B, Grasbeck R. Proteinuria
in cubilin-deficient patients with selective vitamin B12 malabsorption.
Pediatr Nephrol. 2003;18:417–21.
17. Levin-Iaina N, Dinour D, Morduchowicz G, Ganon L, Holtzman EJ. Molecular
study of proteinuria in patients treated with B12 supplements: do not
forget megaloblastic anemia type 1. Nephron Clin Pract. 2011;118:c67–71.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
